This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Vertex Arthritis Pill Shines in Mid-Stage Study

Stocks in this article: VRTXPFERIGLINCYLLY

CAMBRIDGE, Mass. ( TheStreet) -- Vertex Pharmaceuticals (VRTX) appears to have a late but competitive entry in the race to develop a pill for rheumatoid arthritis, a $12 billion treatment market now dominated by injected drugs.

Results from a phase IIa study announced Monday demonstrated that Vertex's drug VX-509 significantly improved the signs and symptoms of the rheumatoid arthritis compared to a placebo after 12 weeks of treatment. Based on the results from this study, Vertex said it will move VX-509 into a larger six-month phase IIb study.

Investors are keen to see whether Vertex has another potential blockbuster drug in its pipeline, following the launch this spring of the hepatitis C drug Incivek. But VX-509 is already playing catch up behind three competing and more advanced rheumatoid arthritis pills being developed separately by Pfizer (PFE) and partnerships between Incyte (INCY) and Eli Lilly (LLY) and Rigel Pharmaceuticals (RIGL) and AstraZeneca (AZN).

The convenience of treating painful and swollen joints with a pill has the potential to be a very attractive option for the 1.5 million U.S. rheumatoid arthritis patients who now rely on regular injections to treat their chronic disease. A pill that has comparable efficacy and safety to injections could generate billions of dollars in peak sales.

VX-509 belongs to a class of oral drugs that work by blocking a family of enzymes known as Janus kinases, or JAK, known to cause inflammation. Vertex designed VX-509 to be a more selective inhibitor of JAK than similar drugs from Pfizer and Incyte/Lilly, which may translate into VX-509 improving symptoms of rheumatoid arthritis with fewer side effects, the company says.

The Pfizer drug, tofacitinib, is already through phase III studies and the company is expected to seek U.S. approval by the end of the year.

The results from VX-509's phase IIa study announced Monday are the first look at the drug's clinical profile in patients. The study enrolled 204 patients with moderate to severe arthritis that failed to respond to at least one prior therapy. The study includes four different doses of VX-509, each given twice a day plus a placebo arm for comparison.

Efficacy of VX-509 was measured after 12 weeks of treatment using a so-called ACR20 score, which is the percentage of patients who achieve a minimum 20% improvement in symptoms. The change from baseline in improvement in DAS28, a measure of rheumatoid arthritis disease activity, is also being assessed in the VX-509 study.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,814.94 -2.96 -0.02%
S&P 500 2,067.03 -2.38 -0.12%
NASDAQ 4,758.2520 +3.36 0.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs